The company has pointed to studies indicating
that transferrin might be useful in transporting
drugs as well, especially to cancer cells. The
tighter the focus on drug transport, the more
efficient and the less destructive therapy can be.
Kamada manager David Tzur commented that the
company is in preliminary stages of adapting the
process of transferrin production for use in
humans and in drugs.
Kamada recently floated on the Tel Aviv Stock
Exchange, raising $7.0m. at a company value of
$19m. and has recently completed a $3.4 million
private placement led by Leon Recanati's
GlenRock Fund.
Rehovot-based Kamada (TASE:KMDA) announced its
first order, for about $225,000, for its
Transferrin protein. The customer will be using
the transferrin in advanced clinical trials of a
cancer drug. Transferrin is a protein naturally
found in the plasma, that transfers iron through
the bloodstream to the organs, such as the liver
and bone marrow. Cancer is one condition that can
depress transferrin levels in the blood, leading
to anemia.